1. B.J. Hunt and K.M. Jurd Endothelial cell activation, British Medical Journal, vol. 316, no. 7141, pp. 1328–1329, 1998.
2. N.N. Huynh, E.E. Harris, J.F.P. Chin-Dusting, and K.L. Andrews, The vascular effects of different arginase inhibitors in rat i/ated aorta and mesenteric arteries, British Journal of Pharmacology, vol. 156, no. 1, pp. 84–93, 2009.
3. X.F. Ming, A.G. Rajapakse, J.M. Carvas, J. Ruffieux, and Z. Yang Inhibition of S6K1 accounts partially for the anti-inflammatory effects of the arginase inhibitor L-norvaline BMC Cardiovascular Disorders, vol. 9, article 12, 2009.
4. M.V. Pokrovskil, T.G. Pokrovskaya, V.I. Kochkarov, and E.B. Artyushkova Endothelioprotective properties of L-arginine on a nitric oxide deficiency model The Experimental and Clinical Pharmacology, vol. 71, no. 2, pp. 29–31, 2008.
5. M.V. Pokrovskii, V.I. Kochkarov, T.G. Pokrovskaya et al. Comparative study of potential endothelioprotectors and impaza in modeled nitric oxide defi ciency Bulletin of Experimental Biology and Medicine, vol. 148, no. 3, pp. 514–517, 2009.
6. Weeks J.L., Zoraghi R., Beasley A., et al. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Int I Impot Res 2004.